Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

Rhea-AI Summary

Impel NeuroPharma (NASDAQ: IMPL) will host a live webcast on March 24, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results. The company focuses on developing therapies for high unmet medical needs, especially in central nervous system diseases. Impel's current offerings include Trudhesa™, an approved nasal spray for migraine treatment, and ongoing development of INP105 for autism-related agitation and INP107 for Parkinson’s OFF episodes. The webcast will be accessible via the Investor section of their website.

Positive

• Live webcast scheduled for March 24, 2022, to discuss Q4 and full year 2021 financial results.
• Development of treatments targeting high unmet medical needs in central nervous system diseases.

Negative

• None.

SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Thursday, March 24, 2022, at 8:30 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update.

The conference call may be accessed by dialling 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 5542868. A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.

About Impel NeuroPharma

Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: christina.tartaglia@sternir.com

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com

FAQ

When will Impel NeuroPharma report its Q4 and full year 2021 financial results?

Impel NeuroPharma will report its Q4 and full year 2021 financial results on March 24, 2022.

How can I access the live webcast for Impel NeuroPharma's financial results?

The live webcast can be accessed on the Investor section of Impel NeuroPharma's website.

What is Trudhesa™ and its approved use?

Trudhesa™ is a nasal spray approved for the acute treatment of migraine with or without aura in adults.

What therapies is Impel NeuroPharma developing apart from Trudhesa™?

Impel is developing INP105 for agitation in autism patients and INP107 for OFF episodes in Parkinson's disease.